Xenon Pharmaceuticals (XENE) Current Deferred Revenue (2013 - 2021)

Xenon Pharmaceuticals (XENE) has 6 years of Current Deferred Revenue data on file, last reported at $2.2 million in Q3 2021.

• Current Deferred Revenue for Q3 2021 came in at $2.2 million, down 70.43% year-over-year; the trailing twelve-month figure through Sep 2021 was $2.2 million (down 70.43% YoY), and the FY2020 annual result was $3.6 million, down 87.76% from the prior year.
• Current Deferred Revenue retreated to $2.2 million in Q3 2021 per XENE's latest filing, from $3.0 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $29.7 million in Q4 2019 and troughed at $2.2 million in Q3 2021.
• A 3-year average of $10.9 million and a median of $5.5 million in 2020 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2020 and 2021: Current Deferred Revenue plunged 87.76% in 2020, then slumped 70.43% in 2021.
• A 3-year view of Current Deferred Revenue shows it stood at $29.7 million in 2019, then sank by 87.76% to $3.6 million in 2020, then plunged by 39.54% to $2.2 million in 2021.
• Business Quant data shows XENE's Current Deferred Revenue at $2.2 million in Q3 2021, $3.0 million in Q2 2021, and $3.6 million in Q1 2021.